HNGE — Stock Film
STOCK FILMSCENE 1/11HNGE · $88.35
Stock Expert AI presents
HNGE
Hinge Health, Inc
~4 min film100% real numbers0 jargon
WHAT DOES THIS COMPANY DO?
Hinge Health, Inc. A quick introduction.

On the stock market since 2025, it operates in the world of health and science. It has 1,437 employees. Now — the numbers.

on the stock market since 2025
1,437 employees
$6.8B market value
Revenue last year:
$0
The loss that same year:
$0
For every $1 it earns, the company spends $1.9.

The company closed last year at a loss: costs ran above sales. The picture changes only if spending is reined in.

In the vault right now:
$0
DEBT: $8.0M
At this pace, that money lasts less than a year.

Before the clock runs out, either sales must climb sharply or new money must come in. This is the most critical line in the whole picture.

Every quarter, analysts set a profit bar.
How many of the last 6 did the company clear?
5 / 6
EXPECTATIONS MET OR BEATEN
5
May 2025
Aug 2025
Nov 2025
Feb 2026
May 2026
Aug 2026
5 TIMES IN THE LAST 6 QUARTERS
It clears the bar, quarter after quarter.
INSIDE THE REPORT CARD

We compared this company with its own sector across five subjects.

A score of 50 means class average.

BUSINESS QUALITY
94
very strong

Profit power and business quality lead the class.

FINANCIAL STRENGTH
90
very strong

A solid grade overall — yet the debt outweighs the cash. The strength here comes from earnings power.

VALUATION
62
average

The price isn’t cheap next to earnings — that’s why this grade sits in the middle.

GROWTH
59
average

There is growth, but not at top-of-the-class tempo.

PRICE MOMENTUM
89
very strong

The stock has been running stronger than the market lately.

No real weak spot in any of the five subjects — a balanced report card.

THE COUNCIL REVIEW
9

angles, checked one by one.

The 4 that stand out are on screen; the rest came back neutral.

The council scores out of 10; report-card grades are out of 100.

STRENGTHS
Sales are growing fast8/10
Heavy investment in the future10/10
Few are betting against it10/10
WEAK SPOTS
Executives aren’t buying3/10
WORTH WATCHING

Executive Buying: The trades send no strong signal of confidence.

THE FIVE-YEAR JOURNEY
Bumpy, but the direction is up.

The stock trades near its peak today. For long-term holders the ride has paid off so far — though past performance guarantees nothing about the future.

1
THE BRIGHT SIDE · 1/2
Sales keep climbing

Over the last 3 years, sales grew about 42% a year on average.

2
THE BRIGHT SIDE · 2/2
Sales are holding up

The company sells $587.9M a year; the problem isn’t sales — it’s costs running above that number.

1
THE RISKS · 1/3
The losses continue

A loss of $528.3M against $587.9M in annual sales.

2
THE RISKS · 2/3
The cash has a countdown

At the current pace of spending, the cash lasts less than a year. After that, the company needs to find new money.

3
THE RISKS · 3/3
Executives lean toward selling

Over the last 12 months, executives reported 192 sells against just 63 buys. Not an alarm bell by itself, but a number worth watching.

FINALE · THE GRADE
A
0 / 100 · MoonshotScore

On our five-subject report card, HNGE sits near the top of the class. A high grade doesn’t mean “guaranteed win” — it means “the evidence looks strong for now.”

The takeaway: HNGE has solid sales but closed last year at a loss. The road back to profit runs through spending discipline.

The total grade weighs these five subjects against the sector — it isn’t a simple average of the five.

What would you like to do next?
Open the stock page →
This was a film — not investment advice.
Data: FMP & company filings
Aug 21, 2026 · stockexpertai.com · Stock Film